Iron Deficiency Anemia Clinical Trial
— IPPERUOfficial title:
Iron Bioavailability From Iron Bio-fortified Irish Potato in Peruvian Women Between 18-25 Years of Age.
Verified date | May 2020 |
Source | Swiss Federal Institute of Technology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To combat iron deficiency in Low and Middle-Income Countries, sustainable food-based solutions have to be implemented to serve populations, not only individuals. One solution is the introduction of iron biofortified staple crops on market level. Before market level introduction, the bioavailability of iron in the new biofortified Irish Potato (IP) breed needs to be assessed. In this study the investigator compares the fractional and total iron absorption after extrinsic stable isotope labelling of the new biofortified high iron IP variety and a normal market level IP variety. The study is conducted in Peruvian women of reproductive age with marginal iron status.
Status | Completed |
Enrollment | 36 |
Est. completion date | August 8, 2019 |
Est. primary completion date | August 8, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 25 Years |
Eligibility |
Inclusion Criteria: 1. Woman aged 18-25 years old. 2. Low/marginal iron status: serum ferritin (SF) = 25 µg/L. 3. Normal BMI for age (18.5-25.0 kg/m2). 4. Weight less than 65 kg. We will give equal amounts of stable isotopes to each study participant and therefore need to set a limit on body weight in order to achieve measurable isotope enrichment in erythrocytes. 5. Willing and able to commute to the meal distribution/health centre site. 6. Able to understand and to sign written concept prior to trial entry. 7. Informed consent signed. 8. Prepared to use contraceptives for the duration of the study Exclusion Criteria: 1. Severe anaemia Hb <107.2 g/L (adjusted for meters above sea level) 2. Inflammation/infection (CRP > 5 mg/100 ml). 3. Relevant digestive (intestinal, gastric, hepatic or pancreatic), renal, metabolic disease, and any other problem that will interfere with the study as determined by the screening visit and by self-report from the subjects. 4. Pregnant (urine test before entering the study) or breast-feeding. 5. Any medication or supplement which may impact iron metabolism. 6. Unwilling to discontinue vitamin and minerals supplements at least two weeks prior to the study start, as ascertained at the screening visit. 7. Significant blood losses over the past 6 months (i.e. trauma, major surgery, blood donation). 8. Subject who cannot be expected to comply with study procedures. 9. Presence of fever (>37.5 °C) on the first study day |
Country | Name | City | State |
---|---|---|---|
Peru | Instituto de Investigacion Nutricional | Lima |
Lead Sponsor | Collaborator |
---|---|
Swiss Federal Institute of Technology | Genetics, Genomics and Crop Improvement Program, International Potato Center, Lima, Peru, Instituto de Investigacion Nutricional, Lima, Peru, Quadram Institute Bioscience, United States Agency for International Development (USAID) |
Peru,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fractional iron absorption from both Irish Potato test meals | Proportion of stable isotope administered with test meals that has been incorporate into erythrocytes 14 days after completion of specific test meal feeding period | Measured 2 weeks after completion of feeding day sequence. Sequence consist of 2 times 10 feeding days. | |
Primary | Total iron absorption from both Irish Potato test meals | Amount of iron absorbed (mg) from the labelled test meals | Measured 2 weeks after completion of feeding day sequence. Sequence consist of 2 times 10 feeding days. | |
Secondary | Concentration of plasma ferritin level | Iron status marker | screening (-1), day 1 (baseline), day 15 (before switch to other test meal type) day 26 (last feeding day) and day 40 (14 days after last test meal consumption). | |
Secondary | Concentration of plasma CRP level | Inflammation status marker | screening (-1), day 1 (baseline), day 15 (before switch to other test meal type) day 26 (last feeding day) and day 40 (14 days after last test meal consumption). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06027801 -
Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity
|
N/A | |
Completed |
NCT02282553 -
Gastric Capsule Examination for Iron Deficiency Anaemia
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT04913649 -
Intravenous Iron to Treat Postoperative Anemia in Older Cardiac Surgery Patients
|
Phase 4 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01438645 -
ScopeGuide-assisted Colonoscopy Versus Conventional Colonoscopy
|
N/A | |
Completed |
NCT01307007 -
Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding
|
Phase 2 | |
Completed |
NCT00982007 -
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)
|
Phase 3 | |
Completed |
NCT00198848 -
Iron Supplementation Among Adolescent Girls in India
|
N/A | |
Completed |
NCT01166451 -
The Anemia Control Program: High or Low Iron Supplementation
|
N/A | |
Recruiting |
NCT03893045 -
A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
|
Phase 3 | |
Recruiting |
NCT03817957 -
Postoperative i.v. Iron Substitution in Patients With Diagnosed Iron Deficiency
|
Phase 3 | |
Completed |
NCT03819530 -
Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study
|
N/A | |
Completed |
NCT03618914 -
Anemia and Inflammation
|
||
Completed |
NCT03940430 -
Lactoferrin Versus Ferrous Sulfate in Management of Iron Deficiency Anemia Among Female Medical Ain Shams Students
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03873584 -
Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
|
||
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Completed |
NCT03237065 -
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia
|
Phase 3 | |
Completed |
NCT05153278 -
IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department
|